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Abstract
Islet transplantation is a promising therapeutic option for type 1 diabetes mellitus, yet
the current delivery into the hepatic portal vasculature is limited by poor engraftment.
Biomaterials have been used as a means to promote engraftment and function at
extrahepatic sites, with strategies being categorized as encapsulation or microporous
scaffolds that can either isolate or integrate islets with the host tissue, respectively.
Although these approaches are typically studied separately using distinct material
platforms, herein, we developed nondegradable polyethylene glycol (PEG)‐based
hydrogels for islet encapsulation or as microporous scaffolds for islet seeding to
compare the initial engraftment and function of islets in syngeneic diabetic mice.
Normoglycemia was restored with transplantation of islets within either encapsulating or
microporous hydrogels containing 700 islet equivalents (IEQ), with transplantation on
microporous hydrogels producing lower blood glucose levels at earlier times. A glucose
challenge test at 1 month after transplant indicated that encapsulated islets had a delay
in glucose‐stimulated insulin secretion, whereas microporous hydrogels restored
normoglycemia in times consistent with native pancreata. Encapsulated islets remained
isolated from the host tissue, whereas the microporous scaffolds allowed for
revascularization of the islets after transplant. Finally, we compared the inflammatory
response after transplantation for the two systems and noted that microporous
hydrogels had a substantially increased presence of neutrophils. Collectively, these
findings suggest that both encapsulation and microporous PEG scaffold designs allow for
stable engraftment of syngeneic islets and the ability to restore normoglycemia, yet the
architecture influences islet function and responsiveness after transplantation.
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1 | INTRODUCTION
Type 1 diabetes mellitus is an autoimmune disease that impacts 5%–10%
of diabetic patients and destroys pancreatic beta cells, rendering patients
unable to regulate blood glucose levels (Shapiro, Pokrywczynska, &
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Ricordi, 2016). Despite the use of exogenous insulin and the develop-
ment of insulin pumps, tight control of normal blood glucose levels and
secondary complications remain a concern. Alternatively, islet trans-
plantation into the hepatic portal vein has been used to restore
endogenous insulin production and aid in maintenance of normoglycemia
and the prevention of severe hypoglycemic events (Gibly, Graham et al.,
2011; Hering et al., 2016). However, this procedure is not widely used
clinically because of poor survival and engraftment of transplanted islets
in the hepatic vasculature. On injection into the hepatic portal vein,
transplanted islets are subject to the instant blood inflammatory
response (IBMIR), which can contribute to the loss of more than 60%
of the islets within days after transplant (Gibly, Graham et al., 2011).
IBMIR promotes a proinflammatory environment, which then leads to
the activation of adaptive immunity and additional injury to islets.
Challenges associated with delivery of islets into the liver have
motivated the development of extrahepatic sites conducive to islet
engraftment to prevent IBMIR‐mediated destruction of islets and
improve clinical outcomes (Berman et al., 2016).
Biomaterial‐based strategies have been used as a means to provide
a controlled environment for the transplantation of islets into
extrahepatic sites. A variety of scaffold materials have been used to
localize islets in extrahepatic locations, including the kidney capsule and
omentum, and restore normoglycemia in diabetic rodent models
(Blomeier et al., 2006; Gibly, Zhang et al., 2011; Pedraza et al., 2013;
Phelps, Headen, Taylor, Thulé, & García, 2013; Rios, Zhang, Luo, & Shea,
2016; Weaver et al., 2017). The design of these scaffolds has
implications for islet engraftment. Two of the more common scaffold
designs used for housing islets involve either encapsulating or
microporous biomaterials. Encapsulating materials protect islets from
direct contact with host immune cells, yet permit efflux of insulin and
exchange of metabolites. Micro‐ and macroencapsulation approaches
have been attempted in large‐animal models and clinically with mass
transport being a challenge (Buder, Alexander, Krishnan, Chapman, &
Lakey, 2013; Song & Roy, 2015; Yang & Yoon, 2015), along with long‐
term graft function despite refinements in specific immunosuppressive
drugs and islet dosage used for transplantation (Brennan et al., 2016;
Desai & Shea, 2016; Ryan et al., 2005; Yang & Yoon, 2015).
Alternatively, microporous scaffolds can be used to seed islets and
permit infiltration of host tissue and vasculature around transplanted
cells, which reduces the challenges related to mass transport. In the
context of islet transplantation, microporous poly(lactide‐co‐glycolide)
(PLG) scaffolds have demonstrated efficacy in vivo in mouse and porcine
models of diabetes (Blomeier et al., 2006; Gibly, Zhang et al., 2011;
Graham et al., 2013; Hlavaty et al., 2014; Liu et al., 2016). However,
microporous scaffolds with seeded cells are subject to infiltration by
host immune cells, which can impact islet engraftment and function.
Strategies to use encapsulation, in combination with a porous
architecture for vascular growth near encapsulated islets, have been
examined (Rios et al., 2016). A direct comparison of the relative efficacy
for the encapsulation and microporous approaches has been challenging
as the material platforms are often distinct for the two systems.
In this report, we investigated islet function and the host response
as a function of the delivery platform, and have used a common
material platform of nondegradable polyethylene glycol (PEG) hydro-
gels. An encapsulating hydrogel representative of macroencapsulation
strategies was fabricated from PEG using a cross‐linking chemistry
that is compatible with cells. A microporous scaffold was created from
PEG using a particulate leaching strategy to create pores that allow for
cell infiltration and islet integration with the host (Blomeier et al.,
2006; Desai & Shea, 2016; Rios et al., 2016). A syngeneic transplant
model was used to focus on engraftment and function as a biomaterial
platform and avoid loss of graft function due to immune rejection.
Islets were transplanted into an extrahepatic site (i.e., epididymal fat
pad) of diabetic mice and the function was followed during a 30‐day
period. In addition, we characterized the innate immune cell response
using flow cytometry to identify the host cells populating the graft and
their relative abundance for the two material platforms. The use of
syngeneic islets transplanted on similar materials provides insight into
how the architecture of the cell delivery system can influence islet
engraftment and function.
2 | MATERIALS AND METHODS
2.1 | Encapsulating and microporous hydrogel
fabrication
Encapsulated hydrogels were formed by mixing PEG‐maleimide
(4‐arm, 20 kDa MW; JenKem Technology USA, Plano, TX) and amino
acid sequence: cysteine‐glycine‐arginine‐glycine-aspartic acid‐serine
(CGRGDS) (CelTek Peptides, Franklin, TN) in the N‐2‐hydroxyethylpiper-
azine‐Nʹ‐2‐ethanesulfonic acid (HEPES) buffer (pH 7.2) to yield a final
PEG concentration of 10% (wt/vol) and amino acid sequence: arginine‐
glycine‐aspartic acid (RGD) concentration of 5mM. The PEG‐CGRGDS
solution was allowed to react via Michael‐type addition for 5min at room
temperature and then stored on ice. Next, the functionalized PEG
precursor was added to sedimented islets in an Eppendorf tube (in
approximately 6 μl of Hank’s balanced salt solution (HBSS) 1X media
(Corning, Corning, NY) supplemented with 10% fetal bovine serum [FBS]).
The bottom of a disc‐shaped polydimethylsiloxane (PDMS) mold
(diameter = 5mm; height = 1mm) was covered with 3 µl of amino acid
sequence: tyrosine‐lysine‐asparagine‐arginine (YKNR) nondegradable
peptide crosslinker solution (GCYKNRGCYKNRCG, custom synthesis,
and purification by CelTek peptides). The peptide contained tyrosine (Y)
and asparagine (N) amino acids in the D‐configuration to prevent cleavage
from plasmin, which inhibits hydrogel degradation (Shikanov, Smith, Xu,
Woodruff, & Shea, 2011). The PEG precursor containing islets was added
to the mold containing the YKNR solution and an additional 3 µl of YKNR
was added on top for a final YKNR concentration of 9.6mM. The
hydrogel was incubated at 37°C for 30min to allow the cross‐linking
reaction to reach completion. Final gel volume was approximately 25 μl.
Microporous PEG hydrogels were fabricated by dissolving
20‐kDa 4‐arm PEG‐maleimide (JenKem Technology USA) in the
HEPES buffer for a final concentration of 20% (wt/vol). The
photoinitiator, Irgacure 2959 (BASF, Florham Park, NJ) was dissolved
in N‐vinylpyrrolidone at a concentration of 600mg/ml and added to
the PEG precursor solution for a final concentration of 1 wt%. NaCl
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was added to the PEG precursor to make a saturated solution. Forty
milligrams of NaCl particles (sieved to a diameter between 250 and
425 µm) was then added to a polydimethylsiloxane mold (diameter =
5mm; height = 1mm), and 10 µl of the saturated PEG solution was
added. After irradiation with UV light, salt was leached from the
scaffolds in ultrapure water for two 10‐min washes. Final gel volume
was approximately 25 µl.
2.2 | Islet isolation and transplantation
Islets were isolated from healthy 10–12 week old male and female
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) after standard
islet isolation procedures. Male C57BL/6J recipient mice were
between 14–18 weeks of age. Four days before islet transplantation,
recipient mice were injected with 220mg/kg of streptozotocin (Sigma
Aldrich, St. Louis, MO) to chemically induce irreversible diabetes.
Nonfasting blood glucose levels were taken using a OneTouch Basic
Glucose Monitor (Aviva, West Des Moines, IA) and only those mice
with a measurement of 300mg/dl or greater on consecutive days (day
before and day of transplant) were used as recipients. Normoglycemia
was denoted as <200mg/dl in syngeneic studies. Hydrogel materials,
encapsulating or microporous, contained either 700 islet equivalent
(IEQ). Encapsulating hydrogels were submersed in supplemented
media for at least 5min before transplantation. To load microporous
hydrogels, islets were concentrated in 30 μl of supplemented media
and applied to the top of a dehydrated hydrogel. Supplemented media
contained Connaught Medical Research Laboratories (CMRL) 1066,
10% FBS, 1% penicillin–streptomycin, 25mM of HEPES (Corning), and
2mM of L‐Glutamine (Sigma Aldrich). Each mouse received one gel
into the fat pad transplantation site. All studies were approved by the
Northwestern University Animal Care and Use Committee or the
University of Michigan Unit for Laboratory Animal Medicine.
2.3 | Intraperitoneal glucose tolerance test
Intraperitoneal glucose tolerance tests (IPGTTs) were performed at 4
weeks after transplantation to assess the ability of the islet grafts to
respond to glucose challenges. A D‐glucose solution (250mg/ml sterile
phosphate buffered saline [PBS] (−/−)) was created for injection. After
a 3‐hr fast period, 2 g/kg of D‐glucose was injected intraperitoneally.
Blood glucose levels were measured at baseline (before injection), 15,
30, 60, 90, 120, and 150min after the glucose injection.
2.4 | Immunohistochemistry
Scaffolds were harvested from euthanized mice and immediately
snap frozen in isopentane at −20°C to preserve tissue architecture.
Frozen scaffolds were embedded in Tissue‐Tek O.C.T. (Thermo Fisher
Scientific, Waltham, MA) supplemented with sucrose. Cryosections
(14 μm) were prepared and stored at −20°C until staining.
Representative sections were fixed in 4% PFA and blocked with
10% normal donkey serum and 0.1% Triton‐X in PBS before staining
with primary antibodies. Sections were stained with guinea pig
polyclonal anti‐swine insulin (Jackson Labs, West Grove, PA, 1:250)
and Hoechst for nuclear counterstaining (Invitrogen, Carlsbad, CA,
1:2,000). Dylight donkey anti‐guinea pig 488 (Jackson Labs, West
Grove, PA, 1:400) was used as a secondary antibody for visualization.
3 | FLOW CYTOMETRY
Mice were euthanized by cervical dislocation under isoflurane‐induced
anesthesia. Tissue was dissociated into a single cell suspension. Tissues
were harvested immediately and stored in HBSS on ice. The resulting
tissue homogenate was filtered through a 70‐μm cell strainer and
washed with magnetic‐activated cell sorting (MACS) (PBS supplemen-
ted with 2mM ethylenediamine tetraacetic acid (EDTA) and 0.5%
bovine serum albumin (BSA)). For scaffold implants and adipose tissue,
enzymatic digestion was used to create a single cell suspension.
Tissues were weighed and placed into a petri dish with 0.5ml of 10
mg/ml collagenase type II (Sigma Aldrich) and 2.5ml of digestion
buffer (HBSS with calcium chloride and magnesium chloride [Thermo
Fisher Scientific] supplemented with 0.5% BSA). The tissue was finely
shredded and transferred to a 15‐ml conical tube. The dish was
washed with 2ml of digestion buffer and added to tissue homogenate
to bring final concentration of collagenase to 1mg/ml. The tissue was
incubated in a 37°C water bath for 30min with gentle shaking every 5
min. In total, 100 μl of 0.5M EDTA was added to each tube to a final
concentration of 10mM and incubated for an additional 5min at 37°C.
The tissue homogenate was strained through a 70‐μm filter and
washed with MACS. The resulting cell pellets were then incubated
with a 1‐ml ammonium‐chloride‐potassium (ACK) buffer on ice to lyse
the red blood cells and washed with MACS. In preparation for staining
with live/dead fixable stain, cells were washed with PBS.
Live/dead fixable violet stain (Thermo Fisher Scientific) was used
for the removal of dead cells from the analysis. The Foxp3/
transcription factor staining buffer (Ebioscience, Waltham, MA) was
used for cells requiring intracellular staining. The following anti-
bodies (clone) were purchased for analysis from Biolegend (San
Diego, CA) or Ebioscience: CD45 (30‐F11), Ly6G (1A8), F4/80 (BM8),
Siglec F, and CD11b. Isotype antibodies were used to establish
gating. Samples were analyzed on the DAKO Cyan 5 ADP.
4 | RESULTS
4.1 | Encapsulating and microporous hydrogel
fabrication
Hydrogels were formed using a 4‐arm PEG‐maleimide, with distinct
cross‐linking strategies applied to create the encapsulating or
microporous constructs. Encapsulating hydrogels were cross‐linked
in a PDMS mold, using a nondegradable, three‐cysteine‐containing
cross‐linking peptide (GCYKNRGCYKNRCG), which has previously
been applied to safely encapsulate islets (Rios et al., 2016). After
incubation in media, the dimensions of the encapsulating gel were
approximately 6mm in diameter and approximately 1.5 mm in height
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(Figure 1a), adequate for implantation into the epididymal fat pad.
Microporous hydrogels were fabricated by mixing salt particles in
functionalized PEG precursor containing photoinitiator. After UV
photopolymerization and salt leaching, the gels had a microporous
architecture (Figure 1b,c). The PEG wt% (wt/vol) of the microporous
hydrogel was 20%, as lower concentrations resulted in collapsible
gels with insufficient integrity for islet seeding. The volume and
dimensions of the microporous hydrogel were the same as the
encapsulating hydrogels. After swelling, microporous hydrogels were
approximately 6.0 mm in diameter and 1.5mm in height, a size
suitable for transplantation into the epididymal fat pad. Furthermore,
resultant hydrogels were sufficiently robust for surgical handling and
implantation.
4.2 | Syngeneic islet transplants in encapsulating
and microporous hydrogels
The engraftment and function of islets encapsulated in bulk
hydrogels or seeded on microporous hydrogels were investigated
by transplantation into the epididymal fat pad of streptozotocin‐
induced diabetic mice. Bulk, nondegradable encapsulating hydrogels
with 700 IEQ reversed diabetes in recipient mice and achieved stable
normoglycemia (i.e., <200mg/dl) by Day 17 (Figure 2a). Salt‐leached,
microporous hydrogels achieved stable normoglycemia by Day 15
after transplant (Figure 2b). Interestingly, the blood glucose dynamics
of the pre‐engraftment period varied between the two designs. For
the encapsulated islets, blood glucose levels remained consistently
elevated above 300mg/dl and were as high as 400mg/dl between
Days 2 and 10 before gradually declining and achieving normogly-
cemia by Day 17. In contrast, the microporous hydrogels attained
near‐normoglycemic blood glucose levels for the first six days after
transplant, transiently rose to a maximum of 300mg/dl between
Days 7 and 14, with re‐establishment of normoglycemia by Day 15. In
both conditions, removal of the hydrogel from the mouse resulted in
a return to hyperglycemia. Collectively, these syngeneic transplant
studies indicated that nondegradable, encapsulating, and micropor-
ous PEG hydrogels support islet function after transplantation into
the epididymal fat pad.
4.3 | Graft function
An IPGTT was performed 30 days after islet transplantation to
investigate glucose responsiveness of the two hydrogel types.
The encapsulated islets had a delayed response to restoring
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F IGURE 1 Encapsulating and microporous hydrogels for islet transplantation. (a) Approximately 10% (wt/vol) bulk PEG hydrogels were
fabricated to encapsulate islets. (b,c) Approximately 20% (wt/vol) microporous gel for islet seeding. Gels were stained with sirius red for
visualization. PEG, polyethylene glycol [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Blood glucose monitoring after transplant with hydrogel materials in fat pad transplantation site of diabetic mice. (a) Bulk,
nondegradable encapsulating hydrogels with 700 IEQ reversed diabetes in recipient mice, with consistent normoglycemia achieved by 3 weeks
after transplant (n = 3; ±SEM). (b) Salt‐leached, microporous hydrogels seeded with 700 IEQ displayed consistent normoglycemia by 3 weeks
after transplant (n = 5 pregraft removal; n = 4 postgraft removal; ±SEM). Recipient mice in both groups reverted to a diabetic state within
2–4 days after hydrogel removal (indicated with a black arrow). IEQ, islet equivalent; SEM, standard error of mean
normoglycemia in response to bolus glucose injection. The blood
glucose levels of diabetic recipient mice with encapsulating hydrogels
peaked at 30min after the injection of glucose versus control mice,
which peaked at 15 min after injection. At the 60‐min time point,
blood glucose levels had decreased toward normoglycemia in both
groups. Normoglycemic blood glucose levels were re‐established at
120 and 90min for the encapsulating gel (175 ± 9mg/dl) (n = 5;
±standard error of mean [SEM]) and the control group (187 ± 4mg/dl)
(n = 4; ±SEM), respectively (Figure 3a). Area under the curve analysis
confirmed statistical differences at 30‐, 60‐, and 90‐min time points
(p ≤ 0.006) between the encapsulating and control group (Supporting
Information Figure 1). Mice transplanted with islets on microporous
gels had no significant difference in blood glucose levels for the
glucose tolerance test relative to the control (Figure 3b). The blood
glucose levels of the microporous hydrogel and control groups
peaked at 15min after the injection of glucose. At 30min, blood
glucose levels for mice decreased toward normoglycemia in both
groups. At 60min, the microporous gel (153 ± 14mg/dl) and the
control group (150 ± 18mg/dl) both achieved normoglycemic levels
and their blood glucose remained normoglycemic for the remainder
of the time points. For control groups, the blood glucose for the
control group relative to the encapsulating hydrogel peaked higher at
15min after injection (352mg/dl) compared with the control group
for the microporous hydrogel (300mg/dl). This delay resulted in a
statistically significant difference at the 60‐, 90‐, 120‐, and 150‐min
time points between the two control groups.
4.4 | Histological analysis of hydrogel explants
Transplanted hydrogels remained intact and were well secured in the
epididymal fat pad on removal (Figure 4a). Insulin‐positive islets were
identified within histological sections for both the encapsulating
(Figure 4b) and microporous hydrogels at Day 30 after the transplant
(Figure 4c). Islets encapsulated within the hydrogel or seeded onto
the microporous hydrogel maintained their morphology, function,
and engraft in the fat pad transplant site. The encapsulated islets
were isolated from the host tissue, whereas islets within the
microporous gel were integrated with the host tissue, as expected.
4.5 | Innate immune cell infiltration in
encapsulating and microporous hydrogels
Given the differences in initial blood glucose levels and the
interaction with host tissue, we investigated the innate immune
response during the initial stages of engraftment changes with
respect to hydrogel architecture. At Day 7, after implantation, the
microporous PEG hydrogel had a large population of neutrophils
(Figure 5). Approximately 56% of recovered leukocytes from
microporous gels expressed a CD11b+ Ly6G+ F4/80– phenotype
consistent with neutrophils compared with only 24% of the cells
isolated along with the encapsulated islet graft. We also investigated
eosinophils and macrophage percentages, as both cell types can be
enriched in adipose tissue. Although not statistically significant, we
also observed a trend toward decreased percentages of eosinophils
(6% vs. 16%) and macrophages (9% vs. 17%) in the encapsulating
hydrogels relative to the microporous hydrogels.
5 | DISCUSSION
In this report, we formulated both encapsulating and microporous
hydrogels from PEG to compare islet engraftment and function for
these two platforms. PEG is soluble with water and can be formed into
a hydrogel in cytocompatible conditions, allowing for both prefabri-
cated and in situ gelation strategies (Weaver et al., 2017; Zhu, 2010).
Both hydrogels were formed as nondegradable on the time frame of
the study. The cross‐linking peptides used to crosslink the encapsulat-
ing hydrogel are not recognizable by endogenous proteases to
produce the nondegradable hydrogel. Islet encapsulation using this
strategy has previously been shown to support high viability (Rios
et al., 2016). We also developed a nondegradable PEG microporous
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F IGURE 3 Glucose responsiveness of encapsulating and
microporous hydrogels 1 month after transplantation. (a)
Postinjection, normoglycemic blood glucose levels (<200 mg/dl) were
achieved by the encapsulating (n = 5; ±SEM) and control (n = 9; ±SEM)
groups at 120 and 90min, respectively. (b) Postinjection,
normoglycemic blood glucose levels were achieved by the
microporous (n = 5 pregraft removal, n = 4 postgraft removal; ±SEM)
and control (n = 4; ±SEM) groups at 60min. SEM, standard error
of mean
hydrogel by incorporating salt as a leachable porogen. These PEG and
salt mixture was cross‐linked with UV and extensively washed to
remove the porogen. The porogen had a diameter in the range of 250–
425 µm, which creates pores sufficiently large for the islets to be
seeded. The seeding of islets into microporous scaffolds occurs with
high efficiency and cell viability (Blomeier et al., 2006; Gibly, Zhang
et al., 2011). Although the same backbone is used for the encapsulat-
ing and microporous hydrogel, the different cross‐linking strategies
may result in distinct crosslink densities and network structure. Cross‐
linking density can impact the behavior of cells and delivery from gels
and is thus a consideration for cell‐laden hydrogel platforms. The
encapsulating hydrogel was formed via Michael‐type addition (a form
of step‐growth polymerization) in which fabrication can be performed
under ambient conditions without the use of free radical initiators.
This cross‐linking approach ultimately results in less defects in the
hydrogel network and better control of the cross‐linking density
compared with photopolymerization (a form of chain polymerization)
used for the microporous hydrogel (Lin & Anseth, 2009). In the context
of islet encapsulation, previous studies have demonstrated that
altering cross‐linking density did not impact encapsulated islet survival
or insulin secretion in vitro, yet it did impact the amount of free
volume available for diffusion (Weber, Lopez, & Anseth, 2009). This
result has direct implications for the delivery of insulin and the time
frames for the restoration of normoglycemia after a glucose load after
transplantation. A high PEG concentration of 20% was used to
fabricate the microporous hydrogel to improve mechanical robustness
for potential clinical use, which may alter cross‐linking density and
thus substrate stiffness (DeForest & Anseth, 2012). However, isolated
islets have been shown to survive and function on or within a wide
range of polymeric biomaterial substrates with varying stiffness both
in vitro and in vivo in numerous studies (Apeldoorn et al., 2015;
Buitinga et al., 2013; Foster & García, 2017; Graham et al., 2013;
Pedraza et al., 2013; Phelps et al., 2013; Smink et al., 2017).
The encapsulating and microporous hydrogels established stable
normoglycemia by the third week after transplantation, though the
microporous hydrogel had lower blood glucose levels at earlier times.
These time scales are consistent with other studies, which transplanted
islets using degradable, encapsulating PEG hydrogels (Phelps et al.,
2013; Weaver et al., 2017). Both material architectures ultimately
restored blood glucose control using 700 IEQ. The encapsulating
hydrogel had the highest blood glucose levels after transplantation,
which has been proposed to be associated with the separation from the
host tissue and the time for the cells to acclimate within the hydrogel
(Pepper, Gala‐Lopez, Ziff, & Shapiro, 2013). Islets transplanted on
microporous hydrogel produced lower blood glucose levels relative to
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F IGURE 4 Insulin‐positive islets identified in explanted hydrogels at Day 10 and 1 month after transplant. (a) Explanted microporous
hydrogel 1 month after transplant. (b) Insulin‐positive islets were identified encapsulating hydrogels removed at Day 32 (~1 month).
(c) Insulin‐positive islets were also identified in microporous hydrogels removed at Day 35 (scale bar: 100 μm) [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 5 Innate immune cell populations in the PEG hydrogel
environment. Percentages of innate cells identified from hydrogels
extracted from hydrogels seven days after implantation. Graph
depicts mean ± SEM. N = 4 hydrogels per condition *<0.05. Statistics
determined by unpaired t test. PEG, polyethylene glycol; SEM,
standard error of mean
the encapsulated platform, yet the blood glucose levels were elevated
relative similar to our previous reports with microporous PLG scaffolds.
The PLG scaffolds result in normoglycemia within a couple of days after
transplantation using a comparable quantity of syngeneic islets
(Blomeier et al., 2006; Gibly, Zhang et al., 2011). Interestingly, the
microporous PEG hydrogels had a modest increase in blood glucose
between Days 7 and 14 before returning to normoglycemic levels. This
rise in blood glucose levels may be associated with our measurements
that more than 50% of CD45+ leukocytes recovered from the
microporous hydrogel at Day 7 are neutrophils. Previous works with
PLG scaffolds have much lower percentages of neutrophils, and the
persistence of neutrophils within the hydrogel is unusual given that
circulating neutrophils typically undergoes spontaneous apoptosis
within five days in the absence of extracellular stimuli. Neutrophils
can cause damage to islets via the release of reactive oxygen species or
inflammatory cytokines that results in the activation of antigen
presenting cells (Gibly, Graham et al., 2011).
Islets transplanted on microporous hydrogels offered greater
responsiveness to blood glucose changes. At Day 30 after transplan-
tation, islets implanted on microporous hydrogels restored normo-
glycemia after bolus glucose delivery with kinetics similar to healthy
mice with endogenous islets. The microporous platform has been
reported to allow the ingrowth of host cells and the revascularization
of transplanted islets (Blomeier et al., 2006; Gibly, Zhang et al.,
2011), which can allow for rapid detection of blood glucose changes
as well as the distribution of secreted insulin. In contrast, the
encapsulated hydrogel showed a delayed recovery to normoglycemia.
The encapsulated hydrogel platform creates distance between the
vasculature and islets, thereby requiring time for the transport of
glucose and insulin that likely contributes to the delay in respon-
siveness in the IPGTT.
The immune cell composition of the grafts at Day 7 was distinct
for the platform. The platforms were formed in a manner that would
make them nondegradable, which are generally thought to initiate a
foreign body response because of the inability of innate cells to
phagocytose the material, leading to a “frustrated” phenotype that
may lead to enhanced secretion of proinflammatory cytokines
(Lynn, Blakney, Kyriakides, & Bryant, 2011; Lynn, Kyriakides, &
Bryant, 2010). A neutrophil‐based response was observed with the
biomaterials implanted in the intraperitoneal space, consistent with
previous reports that indicate that PEG has increased neutrophil
accumulation (Jhunjhunwala et al., 2015; Jiang, Su, Eberhart, &
Tang, 2007). The increased neutrophil recruitment with the
microporous hydrogels was anticipated based on the increased
surface area within the hydrogel, though a contribution of the
crosslink density and network structure may also contribute. High
porosity and hydrophilicity have been suggested as material
properties influencing leukocyte adhesion that would diminish
innate cell responses; however, the nondegradable nature of the
hydrogel could negate the structural aspects of the microporous
scaffolds (Anderson, Rodriguez, & Chang, 2008; Selders, Fetz, Radic,
& Bowlin, 2017). Interestingly, the encapsulated nonporous hydro-
gel did not recruit a similar percentage of neutrophils despite being
composed of the same PEG backbone. This reduction in neutrophils
with encapsulation could suggest that UV cross‐linking of PEG may
introduce a response that is not observed with YKNR cross‐linking.
Slight alterations to the biomaterial chemistry can induce sub-
stantial differences in the host response (Bratlie, York, Invernale,
Langer, & Anderson, 2012; Desai & Shea, 2016). Importantly, the
presence of neutrophils was not sufficient to cause graft failure, as
all recipients of microporous hydrogels seeded with islets recovered
to stable normoglycemia. Despite neutrophils being increased, the
population of macrophages was consistent between the platforms,
with macrophages being a consistent component of a traditional
foreign body response (Anderson et al., 2008; Blakney, Swartz-
lander, & Bryant, 2012; Lynn & Bryant, 2011; McWhorter, Davis, &
Liu, 2015).
6 | CONCLUSION
Herein, the transplantation of islets within encapsulating hydrogels
or on microporous hydrogels, both of which were formed from PEG,
was compared. Both transplantation platforms support the function
of the islets, yet the encapsulation system had initially greater blood
glucose levels relative to the microporous hydrogels. Microporous
hydrogels were able to support lower blood glucose levels at earlier
times, and provided a more rapid restoration of normoglycemia after
an IPGTTs, which likely results from a direct integration with host
tissue. However, the microporous hydrogels had greater numbers of
neutrophils associated with the graft relative to the encapsulating
hydrogels. These results highlight the impact of the material selection
and architecture (encapsulating relative to microporous) on the
engraftment and function of transplanted cells.
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